Abstract: The present disclosure provides oligonucleotide compositions comprising (1) an oligonucleotide of the present disclosure, e.g., an ASO, siRNA, shRNA, DNA or RNA aptamer, gene therapy vector, miRNA, miRNA mimic, antimiR, DNA or RNA decoy, CpG oligonucleotide, or any therapeutic or diagnostic oligonucleotide known in the art, and (ii) a caprylic acid derivative, e.g., 5-CNAC. In some aspects, the oligonucleotide composition is formulated for delivery to the gastrointestinal tract. Thus, some aspects, the present disclosure provides oligonucleotide compositions for oral delivery comprising a therapeutic or diagnostic oligonucleotide (e.g., an ASO) and a caprylic acid derivative (e.g., 5-CNAC or de derivative thereof).
Type:
Application
Filed:
April 21, 2022
Publication date:
December 1, 2022
Applicant:
CiVi Biopharma, Inc.
Inventors:
Henrik OERUM, Stewart Alwyn NOBLE, Charles Lester SHEAR
Abstract: The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.
Type:
Application
Filed:
December 10, 2021
Publication date:
July 7, 2022
Applicant:
CiVi Biopharma, Inc.
Inventors:
Henrik OERUM, Stewart Alwyn NOBLE, Charles Lester SHEAR